· R94.6 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM R94.6 became effective on October 1, 2021. This is the American ICD-10-CM version of R94.6 - other international versions of ICD-10 R94.6 may differ.
· Raised antibody titer. 2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code. R76.0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM …
· R76.8 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM R76.8 became effective on October 1, 2021. This is the American ICD-10-CM version of R76.8 - other international versions of ICD-10 R76.8 may differ. Applicable To Raised level of immunoglobulins NOS
· R71.8 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM R71.8 became effective on October 1, 2021. This is the American ICD-10-CM version of R71.8 - other international versions of ICD-10 R71.8 may differ. Applicable To Abnormal red-cell morphology NOS
This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation.
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Separate serum from cells, and transfer specimen to a plastic transport tube.
Thyroglobulin antibody results should be interpreted in light of the total clinical presentation of the patient, including symptoms, clinical history, data from additional tests, and other appropriate information.
The United States NHANES III survey reported a TgAb prevalence of approximately 10% for the general population, measured by competitive immunoassay. 1 This study reported that 3% of subjects with no risk factors for thyroid disease had detectable TgAb without associated presence of thyroid peroxidase (TPO) antibodies.
1. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH,T (4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002 Feb; 87 (2):489-499. PubMed 11836274
Thyroglobulin (Tg) measurement is intended to aid in monitoring for the presence of orthotropic and/or metastatic thyroid tissues in patients who have had thyroid gland ablation ( using thyroid surgery with or without radioactivity). Measurement of thyroglobulin antibody (TgAb) is used to identify patient samples that may be affected by TgAb ...
The degree of TSH-receptor stimulation from endogenous TSH, recombinant human TSH (rhTSH), human chorionic gonadotropin (during pregnancy) or antibodies that stimulate the TSH receptor (Graves' disease). Measurement of serum Tg is used primarily in the postoperative management and long-term surveillance of patients with DTC.
Thyroglobulin (Tg) is synthesized exclusively by thyroid follicular cells as the precursor protein for thyroid hormone biosynthesis. 1,4,5 The serum Tg reflects the integrated sum of Tg released into the blood stream and is related to three factors: